NP2Neuronal Pentraxin 2
NP2Nucleoside Phosphorylase-2
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
New Delhi, August 2 ( ANI ): The Light Combat Aircraft, Naval Prototype 2 (NP2) today successfully crossed the first step to become Deck Landing compatible on an aircraft carrier.
The Phase II study has been designed to evaluate NP2 Enkephalin for the treatment of severe and chronic cancer pain.
In January, Diamyd Medical said it had dosed the first patient in a phase II randomised, double-blind, placebo-controlled trial with NP2 Enkephalin, which is expected to enrol a total 32 patients at about 10 sites in the USA.
17 January 2011 - Swedish pharmaceutical company Diamyd Medical AB (STO: DIAM-B) said today it has dosed the first subject in a Phase II clinical trial in the USA evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain.
NP2 Enkephalin has shown substantial and sustained reduction in pain scores in a phase I clinical trial aimed at testing the safety of the product.
The first stage of development includes design and fabrication of one Trainer and one Fighter, NP1 and NP2 respectively, along with a Shore Based Test Facility (SBTF) at Goa.
Diamyd said that the encouraging results of the Phase I trial investigating NP2 Enkephalin as a potential therapy for chronic pain, has allowed it to rapidly initiate this new study in cancer patients with chronic severe pain.
19 Otober 2010 - Sweden-based biopharmaceutical company Diamyd Medical AB (STO: DIAM) reported today substantial and sustained pain reduction in the middle and high dose cohorts of Diamyd Medical's Phase I, open-label, dose escalation trial investigating NP2 Enkephalin as a potential therapy for chronic pain.
To verify the positive outcome of the programme, Diamyd Medical plans a multi-center placebo controlled phase II proof-of-concept study with NP2 Enkephalin in the USA.
14 September 2010 - Swedish biotech company Diamyd Medical AB (STO: DIAM B) is in talks with a number of potential partners regarding the development of its product NP2 against cancer pain, CEO Elisabeth Lindner told yesterday news agency Bloomberg.